In patients with T2DM diagnosed with MASH and moderate to severe liver fibrosis confirmed by liver biopsy, AST and ALT levels declined in a time-dependent but dose-independent manner beginning at week 4 after the initiation of tirzepatide 5-10 mg, with further reductions observed beyond week 12 [19]. The gene discussed is GPT; the disease is Hepatic fibrosis.